Compare Charles River Laboratories Intl. Inc (CRL) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Enovix Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $287.4 (market cap $13.46B), while Enovix Corporation trades at $4.83 (market cap $1.06B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 12.7× Enovix Corporation's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| CRL | ENVX | |
|---|---|---|
Market Cap | $13.46B | $1.06B |
Sector | Health | Technology |
52-Week High | $282.00 | $13.19 |
52-Week Low | $145.57 | $3.68 |
Enterprise Value | $16.30B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
ENVX is trading at $4.825, up 3.99% with strong analyst support (75% buy ratings) and a $12.38 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with recent earnings beats and strategic leadership appointments driving optimism. Revenue growth remains modest at $31.82M for 2025, but significant cash burn and negative margins highlight execution risks as the company scales battery production.
The outlook balances high growth potential in advanced battery technology against substantial financial losses. Investment opportunity lies in market leadership in silicon-anode batteries and recent operational improvements, while risks include persistent cash burn and competitive pressures in the evolving energy storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
